Melatonin — A Standard Treatment Adjunct for COVID-19?

STORY AT-A-GLANCE

  • Recent research suggests melatonin may be an important adjunct to COVID-19 treatment
  • Patients hospitalized with COVID-19 pneumonia who were given high-dose melatonin as an adjunct therapy to standard of care improved within four to five days, and all survived
  • Melatonin inhibits the cytokine storm associated with critical SARS-CoV-2 infection. It also inhibits sepsis (blood poisoning), associated with an overactive immune response
  • Melatonin helps prevent mitochondrial impairment, energy failure and apoptosis (programmed cell death) in mitochondria damaged by oxidation
  • Melatonin also helps regulate and improve risk factors for severe COVID-19, such as high blood pressure, insulin resistance and diabetes

Continue reading